Sat­suma backs away from com­mer­cial ef­forts af­ter mi­graine can­di­date fails to hit pri­ma­ry end­point

Two years ago, Sat­suma Phar­ma­ceu­ti­cals had a Phase III fail­ure for a nasal drug in­tend­ed to treat mi­graines, and now it seems the com­pa­ny has hit an­oth­er road­block.

Ac­cord­ing to the South San Fran­cis­co biotech on Mon­day, its can­di­date STS101, a nasal pow­der in­tend­ed to treat mi­graines, did not achieve its co-pri­ma­ry end­points: free­dom from pain and free­dom from most both­er­some symp­toms af­ter two hours of be­ing ad­min­is­tered. The re­sults net­ted a p-val­ue of p <0.05.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER